Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy.
about
Composition and histone substrates of polycomb repressive group complexes change during cellular differentiationZNF274 recruits the histone methyltransferase SETDB1 to the 3' ends of ZNF genesPolycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic ImplicationsAlternative splicing of Tcf7l2 transcripts generates protein variants with differential promoter-binding and transcriptional activation properties at Wnt/beta-catenin targetsPolycomb-like 3 promotes polycomb repressive complex 2 binding to CpG islands and embryonic stem cell self-renewalPolycomb repressive complex 2 (PRC2) restricts hematopoietic stem cell activityThe synovial sarcoma-associated SYT-SSX2 oncogene antagonizes the polycomb complex protein Bmi1.Novel sequential ChIP and simplified basic ChIP protocols for promoter co-occupancy and target gene identification in human embryonic stem cells.Histone deacetylase controls adult stem cell aging by balancing the expression of polycomb genes and jumonji domain containing 3Wilms tumor chromatin profiles highlight stem cell properties and a renal developmental network.Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27.Integrative epigenome analysis identifies a Polycomb-targeted differentiation program as a tumor-suppressor event epigenetically inactivated in colorectal cancerDeregulated expression of the polycomb-group protein SUZ12 target genes characterizes mantle cell lymphoma.Site-specific chromatin immunoprecipitation: a selective method to individually analyze neighboring transcription factor binding sites in vivo.Identification of driver and passenger DNA methylation in cancer by epigenomic analysis.Retinoid regulated association of transcriptional co-regulators and the polycomb group protein SUZ12 with the retinoic acid response elements of Hoxa1, RARbeta(2), and Cyp26A1 in F9 embryonal carcinoma cells.Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer.Mutations in the extra sex combs and Enhancer of Polycomb genes increase homologous recombination in somatic cells of Drosophila melanogasterPharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cellsEnhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.ARE/SUZ12 dual specifically-regulated adenoviral TK/GCV system for CML blast crisis cells.Polycomb (PcG) proteins, BMI1 and SUZ12, regulate arsenic-induced cell transformationInhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.Cancer as a manifestation of aberrant chromatin structure.Stem cell chromatin patterns: an instructive mechanism for DNA hypermethylation?Ezh1 and Ezh2 maintain repressive chromatin through different mechanismsGene silencing and Polycomb group proteins: an overview of their structure, mechanisms and phylogenetics.Polycomb and the emerging epigenetics of pancreatic cancer.Reversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis.Epigenetic silencing of CCAAT/enhancer-binding protein delta activity by YY1/polycomb group/DNA methyltransferase complex.Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locusMethylation of homeobox genes is a frequent and early epigenetic event in breast cancer.Tissue-specific regulatory network extractor (TS-REX): a database and software resource for the tissue and cell type-specific investigation of transcription factor-gene networksThe role of maintenance proteins in the preservation of epithelial cell identity during mammary gland remodeling and breast cancer initiation.EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells.Epigenetic factor EPC1 is a master regulator of DNA damage response by interacting with E2F1 to silence death and activate metastasis-related gene signatures.Comprehensive analysis of β-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt/β-catenin signaling.Identification of genes potentially involved in the increased risk of malignancy in NF1-microdeleted patients.Differential control of Wnt target genes involves epigenetic mechanisms and selective promoter occupancy by T-cell factors.
P2860
Q24293278-7694CF0B-82D2-4D05-BFF3-21D8BAF25229Q24318366-82113B4B-FBA2-4D2C-B05E-5458C21A2334Q26801380-0AB8C32A-2665-456A-9825-1AD4104FC5E6Q28506976-4F16EBDE-22BD-4992-B3C8-44BBC88F2783Q28587391-E4267479-4085-473C-8FFB-66806862FCC1Q33328634-46FE1BD4-A47C-49E6-9CC2-7FAF794AF6BCQ33425217-F040AA77-A88C-4C72-BB8D-5708D4BFFA41Q33475969-12BAC85D-77D0-4059-AB49-3F08C316A647Q33716041-755A687D-49F2-42ED-960A-BB31E53AE16EQ33961864-DE7A2319-BBA6-47A8-B393-607E63F0A1BAQ33979536-1CC0A285-E2C4-4067-BA33-5B505654ED4BQ34007733-6F3C3269-1E3C-4C68-BC11-65340E9FFB5BQ34033355-F16C41FF-7991-422D-B870-2950E300C5E5Q34164008-1C68AFE6-C7BA-47D8-9895-708A252A24D7Q34181789-3311700F-CFDD-404A-9742-DBF1D062DF5CQ34273293-D3498C77-E00C-4847-B1AD-6829E09F55C3Q34328025-DEBD4231-0881-4800-A965-7DD4ABF3BF90Q34588653-CDAE6ED0-9D90-4311-B3C9-A933436780C4Q34619655-7F8AC72F-8429-4AEA-AA98-8A76B04DE71DQ34690158-14375BD4-63F0-4C28-8272-80D5453D238EQ35686509-44579F25-DCA2-4CF6-8870-6186AD0BC685Q36234750-2D86B574-19AA-4C09-9707-4710C09DF66DQ36544065-7FAF7255-A208-4EFA-8CA0-29825F6BA386Q36651427-51E6227C-358C-4A63-AF17-FAC4CA337C7FQ36800825-C8068DAC-1878-4285-B8B6-0447761310F9Q36810306-A02B678A-AE5C-44BD-A1CF-CBA172BF6582Q36870334-7C1B65AF-1233-424E-AF1B-296BAD189AF5Q36918656-A2E36C9B-6B6D-475F-9B3F-3DABD3BED8FFQ36924378-6A6C3B22-6D6A-40E8-998B-03E92091DE6AQ37142723-3AB210A7-32EE-411D-AF65-6D913FC19965Q37201056-D2DE02FC-B68B-4F89-8456-23EC4CF04E1BQ37205583-B236F6BC-35F1-4EA5-8B3D-B622C6F3CA2BQ37235411-661D8411-A094-4C90-8327-566AECBD94E3Q37603631-7F9BEC7B-6E2F-476D-AFD4-F796E75C43D6Q37636628-9442B21B-0042-4986-88AA-D825A12BA1E5Q38343552-8CDE1879-BEF4-4626-B006-D630E503C0E4Q38836863-BBB442D4-B22F-4755-A490-14B75C9F12D3Q39030149-96C36E89-FB6B-43B7-8191-7BDCB915F1EBQ39655398-FB9EF42C-5145-44BF-A377-B046FA9046F0Q40070408-302856CF-BC84-471E-9158-9F0F94C1A584
P2860
Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Identification of the polycomb ...... rget for human cancer therapy.
@en
type
label
Identification of the polycomb ...... rget for human cancer therapy.
@en
prefLabel
Identification of the polycomb ...... rget for human cancer therapy.
@en
P1476
Identification of the polycomb ...... rget for human cancer therapy.
@en
P2093
Antonis Kirmizis
Stephanie M Bartley
P304
P577
2003-01-01T00:00:00Z